Humoral immunity and safety of respiratory virus vaccines in systemic lupus erythematosus population: a meta-analysis based on twenty-five observational studies.
Ann Med
; 56(1): 2392882, 2024 Dec.
Article
en En
| MEDLINE
| ID: mdl-39155852
ABSTRACT
BACKGROUND:
Systemic lupus erythematosus (SLE), an extensive autoimmune disorder, compromises viral resistance and alters immune responses post respiratory virus vaccines. This study aims to assess immune response levels and safety in SLE patients following respiratory virus vaccines.METHODS:
Extensive searches, until 1 March 2024, were conducted using PubMed, EMBASE, and Cochrane Library. Outcomes, encompassing seroconversion rate (SCR), antibody and IgG titers, neutralizing antibodies, anti-spike antibodies, anti-receptor binding domain (RBD) IgG, and adverse events, were appraised.RESULTS:
Sixteen articles, comprising 25 observational studies, were included. SLE patients exhibited lower SCR (OR = 0.42, 95%CI 0.26 to 0.69), antibody titers (SMD=-2.84, 95%CI -3.36 to -1.61), and neutralizing antibodies (OR = 0.27, 95%CI 0.13 to 0.56) compared to the healthy population post respiratory virus vaccines. Notably, differences were statistically insignificant for anti-RBD IgG (OR = 1.75, 95%CI 0.10 to 29.42), IgG titers (SMD=-2.54, 95%CI -5.57 to -0.49), anti-spike antibodies (OR = 0.35, 95%CI 0.08 to 1.53), injection site discomfort (OR = 1.03, 95%CI 0.52 to 2.06), fatigue (OR = 1.23, 95%CI 0.74 to 2.03), fever (OR = 1.02, 95%CI 0.64 to 1.63), localized reactions (OR = 0.69, 95%CI 0.37 to 1.30), systemic reactions (OR = 1.00, 95%CI 0.59 to 1.69), allergic reactions (OR = 5.11, 95%CI 0.24 to 107.10), self-reported vaccination-related adverse events (OR = 1.61, 95%CI 0.56 to 4.63), and disease flares after vaccination (OR = 1.00, 95%CI 0.14 to 7.28).CONCLUSION:
Despite the reduced immune response and host protection in SLE patients post-Corona Virus Disease 2019 (COVID-19) and influenza vaccines compared to the healthy population, safety profiles are comparable. Therefore, it is recommended that SLE patients receive COVID-19 and influenza viral vaccines to fortify their resistance.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Estudios Observacionales como Asunto
/
Inmunidad Humoral
/
Lupus Eritematoso Sistémico
/
Anticuerpos Antivirales
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Ann Med
Asunto de la revista:
MEDICINA
Año:
2024
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Reino Unido